Browse studies

Find your next paid study

7 recruiting studies matching your filters

Phase IIa Trial to Evaluate Epcoritamab Administered Before and After CAR-T Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphomas

This study investigates the feasibility and efficacy of epcoritamab treatment before CAR T cells. This study also investigates if, when patients have residual …

Lymphoma, Non-HodgkinRelapsed Diffuse Large B Cell LymphomaRefractory Diffuse Large B-cell Lymphoma+2 more

Estimated

~$10 – $6,250

Abramson Cancer Center at Penn MedicineNCT06458439

Phase 1

Phase I Clinical Trial of Anti-CD19/20/22 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Lymphoid Malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, B-Prolymphocytic Leukemia)

This phase I trial tests the safety, side effects and best infusion dose of genetically engineered cells called anti-CD19/CD20/CD22 chimeric antigen receptor (…

Recurrent Acute Lymphoblastic LeukemiaRecurrent B Acute Lymphoblastic LeukemiaRecurrent B-Cell Prolymphocytic Leukemia+15 more

Estimated

Phase 1

A Phase I Study to Investigate the Safety of the Ubiquitin Activating Enzyme Inhibitor TAK-243 in Adult Solid Tumor and Lymphoma Patients

This phase I trial studies the side effects and best dose of ubiquitin-activating enzyme (UAE) inhibitor TAK-243 (TAK-243) in treating patients with a solid tu…

Advanced LymphomaAdvanced Malignant Solid NeoplasmIndolent Non-Hodgkin Lymphoma+3 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06223542

Phase 2

An Open-Label Phase 2 Trial of Acalabrutinib Plus Obinutuzumab in Patients With Untreated, Low Tumor Burden Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas

This phase II trial studies the effect of acalabrutinib and obinutuzumab in treating patients with follicular lymphoma or other indolent non-Hodgkin lymphoma f…

Grade 1 Follicular LymphomaGrade 2 Follicular LymphomaGrade 3a Follicular Lymphoma+5 more

Estimated

~$10 – $6,250

Emory UniversityNCT04883437

Observational

The Effects of Acute and Chronic Exercise on the Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients

This clinical trial studies the effect of short-term (acute) and long-term (chronic) exercise on immune characteristics and function (phenotype) of patients wi…

Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaIndolent Non-hodgkin Lymphoma

Estimated

~$10 – $6,250

Mayo ClinicNCT05876923

Phase 2

MC230808 Reduced Dose Hypofractionated Radiotherapy (3Gy x 3 Fractions) for Indolent Non-Hodgkin Lymphoma (POSEIDON): A Multisite Phase 2 Randomized Trial

This phase II trial compares the safety, side effects and effectiveness of reduced dose radiation therapy to standard of care dose radiation in treating patien…

Indolent B-Cell Non-Hodgkin LymphomaRecurrent Indolent B-Cell Non-Hodgkin LymphomaRefractory Indolent B-Cell Non-Hodgkin Lymphoma+2 more

Estimated

~$10 – $6,250

Mayo ClinicNCT06386315

Phase 1

Phase 1 Study of the Administration of T Lymphocytes Expressing the Kappa Chimeric Antigen Receptor (CAR) and CD28 Endodomain for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

This study will combine both T cells and antibodies in order to create a more effective treatment. The treatment tested in this study uses modified T-cells cal…

Mantle Cell LymphomaFollicular LymphomaSplenic Marginal Zone Lymphoma+3 more

Estimated

~$10 – $6,250

UNC Lineberger Comprehensive Cancer CenterNCT04223765